1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Modus Therapeutics Holding AB

Modus Therapeutics Holding AB

SSTO:MODTX
0.18
SEK
+0.00
(-2.70%)
-0.16EPS
55.91MMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-1.07
-0.15
-0.66
-0.45
-0.4
-0.17
-0.3
-0.16
Free Cash Flow per Basic Share
-1.08
-0.18
-0.51
-0.53
-0.37
-0.16
-0.29
-0.17
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.07
0.17
0.39
-0.06
0.19
0.02
0.07
0.07
Tangible Book Value per Share
-0.07
0.17
0.39
-0.06
0.19
0.02
0.07
0.07
Basic Weighted Avg Shares
41
41
31
41
45
91
63
110
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-44
-6
-21
-18
-18
-16
-19
-18
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
-3
7
16
-3
18
2
9
10
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
-3
7
16
-3
18
2
9
10
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-182.06
- -
- -
-156.87
-330.89
- -

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
122
122
149
Market Capitalization
37
36
56

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
13
8
13
Cash, Cash Equivalents & STI
11
7
12
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
2
3
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-107.79%
324.47%
Free Cash Flow
- -
29.08%
23.12%
Net Income, GAAP
- -
47.23%
19.29%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.05
-0.03
-0.05
-0.17
2025
-0.08
-0.17
-0.08
-0.04
-0.3
2026
-0.03
-0.03
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
John Öhd
Full Time Employees
2
Sector
Health technology
Industry
Biotechnology
Address
Olof Palmes gata 29 IV Stockholm AB Sweden 111 22
IPO Date
Jul 22, 2021
Website
modustx.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Modus Therapeutics Holding AB (publ) (MODTX.ST) is a clinical-stage biopharmaceutical company focused on developing novel therapies for thrombo-inflammatory diseases. The company develops sebastoparin, a first-in-class direct factor XIa inhibitor designed to prevent thrombosis while preserving hemostasis; and MOD-1001, a proprietary small molecule factor XIa inhibitor for acute treatment of thrombo-inflammatory conditions such as sepsis and COVID-19-related coagulopathy. Its pipeline targets unmet needs in anticoagulation, with programs emphasizing reduced bleeding risk compared to traditional therapies. Founded in 1998 and headquartered in Stockholm, Sweden, Modus Therapeutics operates primarily in Europe with clinical trials conducted internationally. In recent developments, the company advanced its clinical pipeline, including ongoing Phase 2 trials for sebastoparin in 2024-2025, reflecting strategic focus on expanding indications for acute care settings; no major acquisitions, funding rounds, or partnerships were publicly announced in the last 1-2 years, maintaining its independent development trajectory amid biotech sector challenges.